Cleantech Building Materials: LOAN FACILITY DEBT CONVERSION AND ISSUE OF NEW SHARES
29 December 2022
CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN
CLEANTECH BUILDING MATERIALS PLC
LOAN FACILITY DEBT CONVERSIONAND ISSUE OF NEW SHARES
Cleantech Building Materials PLC (“CBM” or the “Company”) announces that the Company has reached an agreement with its loan providers, as disclosed in the CBM Company Description published on 20 December 2016, to convert €2,854,985.78 of outstanding debt, interest, expenses, investment banking and transaction fees into 6,851,965 new ordinary shares of £0.10 nominal par value each in the Company (“Ordinary Shares”), and, in accordance with the provisions of the loan agreement, for the new Ordinary Shares to be issued to a number of parties (the “Conversion”). No such party will hold 5% or more of the Company’s issued share capital. The Company will apply for the 6,851,965 new Ordinary Shares to be admitted to trading on the Exchange.
Following the Conversion, the issued share capital of the Company will be 88,276,936 Ordinary Shares, with no Ordinary Shares held in Treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to, their interest in Ordinary Shares under the Disclosure Guidance and Transparency Rules.
THE DIRECTORS OF CLEANTECH BUILDING MATERIALS PLC ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT
Further information may be found at the Company's website at www.cbm-plc.com
|Cleantech Building Materials plc|
+44 20 3934 6630
|Keswick Global AG (Certified Adviser)||email@example.com|
+43 1 740 408045
|IFC Advisory Limited (Financial PR)|
|+44 20 3934 6630|
The information communicated in this announcement is disclosed in compliance with Rule 4.2.5 of the Nasdaq First North Growth Market Rulebook.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Result of the auction of treasury bills on 30 March 202330.3.2023 10:31:26 CEST | Press release
Bids, sales, stop-rates and prices are presented in the table below: ISINBid Mill. kr. (nominal)SaleStop-rate (per cent)Pro-rataPrice98 18932 DKT 01/06/23 II4,2003,1202.63 100 %99.5708 98 19070 DKT 01/09/23 III5,7005,7002.85 100 %98.8187Total9,9008,820 The sale will settle 3 April 2023.
Resultat af auktion over skatkammerbeviser 30. marts 202330.3.2023 10:31:26 CEST | pressemeddelelse
Bud, salg, skæringsrenter og pris fremgår af nedenstående oversigt: ISINBud mio. kr. (nominelt)SalgSkæringsrente (pct.)Pro-rataKurs98 18932 SKBV 23 / II4.2003.1202,63 100 %99,5708 98 19070 SKBV 23 / III5.7005.7002,85 100 %98,8187I alt9.9008.820 Salget bliver afviklet den 3. april 2023.
Indkaldelse til ordinær generalforsamling i FirstFarms A/S30.3.2023 10:29:46 CEST | pressemeddelelse
Bestyrelsen indkalder hermed til ordinær generalforsamling i FirstFarms A/S, CVR 28 31 25 04. Generalforsamlingen afholdes tirsdag den 25. april 2023 kl. 14.00 på: SAGRO, Majsmarken 1, DK-7190 Billund Den ordinære generalforsamling bliver desuden transmitteret direkte på dansk via webcast gennem selskabets aktionærportal. Transmissionen vil kun dække talerstolen. Dagsorden: 1. Beretning om selskabets virksomhed 2. Forelæggelse af årsrapport med revisionspåtegning til godkendelse og meddelelse afdecharge til bestyrelsen 3. Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport 4. Godkendelse af bestyrelseshonorar 5. Præsentation af og vejledende afstemning om vederlagsrapporten for 2022 6. Valg af medlemmer til bestyrelsen 7. Valg af revisor 8. Forslag fra bestyrelsen a) Bemyndigelse til erhvervelse af egne aktier b) Bemyndigelse til dirigenten 9. Eventuelt Ad 3 Bestyrelsen foreslår, at der af det regnskabsmæssige overskud efter skat på 65
Notice to convene the annual general meeting in FirstFarms A/S30.3.2023 10:29:46 CEST | Press release
The Board of Directors hereby convenes to annual general meeting in FirstFarms A/S, CVR 28 31 25 04. The annual general meeting will be held on Tuesday 25 April 2023 at 2 p.m. in: SAGRO, Majsmarken 1, DK-7190 Billund The Annual General Meeting will also be broadcast live in Danish language via webcast through the company's shareholder portal. The transmission will only cover the rostrum. Agenda: 1. Report on the company’s activities 2. Presentation and adoption of the annual report with auditor’s report for approval and discharge of the Board of Directors from their obligation, having adopted the accounts 3. Decision about utilisation of profit or covering of loss according to the approved annual report 4. Approval of remuneration to the Board of Directors 5. Presentation of and advisory vote on the remuneration report for 2022 6. Election of Board members 7. Election of auditor 8. Proposals from the Board of Directors a) Authorisation to acquire own shares b) Authorisation to the chai
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator30.3.2023 10:24:41 CEST | Press release
Smart Immunereceives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France,30March, 2023 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, announced today that it has been selected by the European Innovation Council (EIC) to receive funding of €17.5 million to accelerate the development of ProTcell to treat life-threatening cancers and infection. The EIC investment was made through its Accelerator Fund, designed to support small and medium enterprises (SMEs), in particular start-ups and spin-out companies, to develop and scale “game-changing” innovations. This last call attracted almost 500 applications across Europe, in all industry sectors. From this pool, 153 were invited to an online interview with the EIC and 32 of them were awarded a grant. Of these, 17 received an equity commitment as